10x Genomics, Inc. (NASDAQ:TXG) Shares Sold by Cwm LLC

Cwm LLC reduced its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 5.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 59,743 shares of the company’s stock after selling 3,418 shares during the period. Cwm LLC owned approximately 0.05% of 10x Genomics worth $3,343,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. UMB Bank n.a. lifted its stake in shares of 10x Genomics by 51.6% during the fourth quarter. UMB Bank n.a. now owns 782 shares of the company’s stock worth $44,000 after buying an additional 266 shares during the period. Allspring Global Investments Holdings LLC acquired a new stake in shares of 10x Genomics during the third quarter worth $146,000. Powell Investment Advisors LLC acquired a new stake in shares of 10x Genomics during the fourth quarter worth $200,000. Bleakley Financial Group LLC acquired a new stake in shares of 10x Genomics during the fourth quarter worth $234,000. Finally, Simplicity Solutions LLC acquired a new stake in shares of 10x Genomics during the fourth quarter worth $234,000. 84.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on TXG shares. Barclays lowered their price objective on shares of 10x Genomics from $55.00 to $45.00 and set an “overweight” rating for the company in a research note on Wednesday, April 10th. Stifel Nicolaus decreased their target price on shares of 10x Genomics from $68.00 to $63.00 and set a “buy” rating for the company in a research report on Friday, February 16th. Finally, Deutsche Bank Aktiengesellschaft decreased their target price on shares of 10x Genomics from $60.00 to $55.00 and set a “buy” rating for the company in a research report on Thursday, April 18th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $60.22.

10x Genomics Stock Down 0.2 %

TXG opened at $27.52 on Thursday. 10x Genomics, Inc. has a fifty-two week low of $26.75 and a fifty-two week high of $63.57. The company has a fifty day moving average of $38.54 and a two-hundred day moving average of $42.71.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings data on Thursday, February 15th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.05). 10x Genomics had a negative net margin of 41.17% and a negative return on equity of 28.82%. The firm had revenue of $183.98 million during the quarter, compared to analysts’ expectations of $182.73 million. During the same period in the previous year, the firm posted ($0.15) EPS. The firm’s quarterly revenue was up 17.8% on a year-over-year basis. Sell-side analysts predict that 10x Genomics, Inc. will post -1.47 earnings per share for the current fiscal year.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, insider Benjamin J. Hindson sold 2,613 shares of 10x Genomics stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $46.34, for a total value of $121,086.42. Following the completion of the transaction, the insider now owns 283,059 shares of the company’s stock, valued at $13,116,954.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CFO Justin J. Mcanear sold 1,865 shares of the business’s stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $46.34, for a total transaction of $86,424.10. Following the completion of the sale, the chief financial officer now owns 95,240 shares of the company’s stock, valued at $4,413,421.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Benjamin J. Hindson sold 2,613 shares of the business’s stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $46.34, for a total transaction of $121,086.42. Following the sale, the insider now directly owns 283,059 shares of the company’s stock, valued at approximately $13,116,954.06. The disclosure for this sale can be found here. Over the last quarter, insiders sold 12,959 shares of company stock valued at $592,806. Corporate insiders own 10.65% of the company’s stock.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.